2Wang H W,Babic A M,Mitchell H A,et al.Elevated soluble ICAM-1 levels induce immune deficiency and increase adiposity in mice[J].FASEB J,2005,19(8):1018-1020.
3Mody N A,Lomakin O,Doggett T A,et al.Mechanics of transient platelet adhesion to von Willebrand factor under flow[J].Biophys J,2005,88(2):1432-1443.
4Del-Rio D,Stewart A J,Pellegrini N.A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress[J].Nutr Metab Cardiovasc Dis,2005,15(4):316-328.
二级参考文献10
1Hiyama A, Takeda J, Kotate Y, et al. A human urinary protease inhibitor (ulinastatin) inhibits neutrophil extracellular release of elastase during cardiopulmonary bypass[J]. J Cardiothorac Vase Anesth, 1997, 11: 580.
2Butler J, Pillci R, Pocker G M, et al. Effects of cardiopu l2 monary bypass on systemic release of neutrophil elastase and tu2mor necrosis factor[J]. J Thorac Cardiovasc Surg, 1993, 105: 25.
3Wan S. Inflammatory response to cardiopulmonary bypass, mech2anisms involved and possible therapeatic strategies[J]. Chest, 1997, 112: 676.
4Tanita T, Song C, Kubo H, et al. Superoxide anion mediates pulmonary vascular permeability caused by neutrophils in cardiopulmonary bypass[J]. Surg Today, 1999, 29: 755.
5Miura M, Sugiura T, Aimi I. Effects of ulinastatin on PMNL and vascular endothelial injury in patients undergoing open heart surgery with CPB[J]. Masui, 1998, 47: 29.
4Sato Y, Ishikawa S, Otaki A, et al. Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokines and postoperative organ injury[ J]. Jpn J Thorac Cardiovasc Surg, 2000, 48 (7) : 428 - 434.
5Landis R C, Haskard D O, Taylor K M. New antiinflammatory and platelet-preserving effects of aprotinin[ J]. Ann Thorac Surg, 2001,72 (2): S1808- S1813.
6Sugita T, Watarida S, Katsuyama K, et al. Effect of a human urinary protease inhibitor(Ulinastatin) on respiratory function in pediatric patients undergoing cardiopulmonary bypass[ J]. J Cardiovasc Surg (Torino), 2002, 43 (4) : 437 - 440.
